Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, ...

Furthermore, mazdutide, the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, has ignited significant research interest in the scientific community ...

About Altimmune Inc. Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesi ...

For instance, glucagon-like peptide-1 (GLP-1) receptor agonists, which have made waves as therapies for diabetes and obesity, appear to hold promise for patients with MASLD and MASH, the authors said.

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve liver-related biomarkers, their ability to reduce the risks for NAFLD ...

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 ...

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve liver-related biomarkers, their ability to reduce the risks for ...

Preclinical studies and large-scale randomized controlled trials have demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1RAs) can improve hepatic steatosis, balloon degeneration, and ...

Like those drugs, survodutide activates an insulin-regulating hormone called GLP-1. But the drug also targets a receptor controlling the hormone glucagon, which could be useful for treating MASH ...